Trial
NCT03658213
To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
AstraZeneca
Collaborators
—
Condition
Breast Cancer
Intervention
ZOLADEX 10.8 mg
Why stopped
CTP of LARES has been out of the expire date, we are trying RWS pathway for the indication expend
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-05-10